Supplementary Table 1. Univariable and multivariable analysis of cohort 1.
| ypCR | ypCR + ypPR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||||
| ypCR (54) | Non-ypCR (197) | p value | OR (95%CI) | p value | ypCR + ypPR (183) | Non-ypCR + ypPR (68) | p value | OR (95%CI) | p value | |
| Age < 65y ≥ 65y Missing |
31 (57.4%) 23 (42.6%) 0 |
136 (69.4%) 60 (30.6%) 0 |
0.10 |
0.51 (0.22–1.17) 1 |
0.11 |
123 (67.6%) 59 (32.4%) 1 |
44 (64.7%) 24 (35.3%) 0 |
0.76 | - | - |
| Sex Female Male |
25 (46.3%) 19 (53.7%) |
78 (39.6%) 119 (60.4%) |
0.43 | - | - |
80 (43.7%) 103 (56.3%) |
23 (33.8%) 45 (66.2%) |
0.19 |
1.39 (0.70–2.79) 1 |
0.35 |
| ECOG 0 ≥ 1 Missing |
18 (33.3%) 36 (66.7%) 0 |
65 (33.7%) 128 (66.3%) 3 |
1.00 | - | - |
60 (33.5%) 119 (66.5%) 4 |
23 (33.8%) 45 (66.2%) 0 |
1.00 | - | - |
| Comorbidities No Yes |
22 (40.7%) 32 (59.3%) |
80 (40.6%) 117 (59.4%) |
1.00 | - | - |
79 (43.2%) 104 (56.8%) |
23 (33.8%) 45 (66.2%) |
0.19 |
1.60 (0.78–3.29) 1 |
0.20 |
| Clinical stage II III |
11 (20.4%) 43 (79.6%) |
39 (19.8%) 158 (80.2%) |
1.00 |
0.76 (0.29–2.03) 1 |
0.59 |
28 (15.3%) 155 (84.7%) |
22 (32.4%) 46 (67.6%) |
0.004 |
0.49 (0.22–1.09) 1 |
0.08 |
| PPI No Yes |
39 (72.1%) 15 (27.8%) |
161 (81.7%) 36 (18.3%) |
0.13 |
1 1.101 (0.42–2.91) |
0.85 |
144 (78.7%) 39 (21.3%) |
56 (82.4%) 12 (17.6%) |
0.60 | - | - |
| PPI >50 No Yes |
47 (87.0%) 7 (13.0%) |
172 (87.3%) 25 (12.7%) |
1.00 | - | - |
157 (85.8%) 26 (14.2%) |
62 (91.2%) 6 (8.8%) |
0.29 | - | - |
| Radiotherapy 3D Other Missing |
42 (77.8%) 12 (22.2%) 0 |
143 (76.5%) 44 (23.5%) 9 |
1.00 | - | - |
143 (80.3%) 35 (19.7%) 5 |
42 (66.7%) 21 (33.3%) 5 |
0.04 |
1 0.39 (0.18–0.83) |
0.01 |
| Time RT – surgery ≤ 8 weeks > 8 weeks Missing |
7 (13.2%) 46 (86.8%) 1 |
21 (11.1%) 168 (88.9%) 7 |
0.63 | - | - |
20 (11.1%) 160 (88.9%) 3 |
8 (12.9%) 54 (87.1%) 6 |
0.65 |
0.52 (0.25–1.10) 1 |
0.08 |
| RT duration ≤ 5 weeks > 5 weeks Missing |
39 (72.2%) 15 (27.8%) 0 |
119 (61.3%) 75 (38.7%) 3 |
0.15 |
2.60 (1.06–6.38) 1 |
0.04 |
109 (60.2%) 72 (39.8%) 2 |
49 (73.1%) 18 (26.9%) 1 |
0.07 | - | - |
| Dose-intensity cap 100% < 100% Missing |
37 (71.2%) 15 (28.8%) 2 |
133 (70.7%) 55 (29.3%) 8 |
1.00 | - | - |
124 (70.1%) 53 (29.9%) 6 |
46 (73.0%) 17 (27.0%) 5 |
0.75 | - | - |
| Clinical responsea No Yes Missing |
20 (40.0%) 30 (60.0%) 4 |
154 (92.2%) 13 (7.8%) 30 |
<0.001 |
1 21.67 (8.92–52.68) |
<0.001 |
22 (13.8%) 137 (86.2%) 24 |
22 (37.9%) 36 (62.1%) 10 |
<0.001 |
1 4.09 (1.91–8.74) |
<0.001 |
a
Clinical complete response was used for ypCR analysis and clinical complete + partial response for ypCR + ypPR analysis
ypCR: pathological complete response; ypPR: pathological partial response; OR: odds ratio; 95%CI: 95% CI; y: years; PPI: proton-pump inhibitors; PPI > 50: use of proton-pump inhibitors > 50% of neoadjuvant therapy duration; RT: radiotherapy; Cap: capecitabine
The bold values represent statistical significant factors associated with ypCR and ypCR+ypPR in univariable and multivariable analysis in cohort 1